|
US2010010202A1
|
|
Human antibodies derived from immunized xenomice
|
|
AU2006207845A1
|
|
CD147 Binding Molecules as Therapeutics
|
|
AU2006203702A1
|
|
Human monoclonal antibodies against oxidized LDL receptor and medicinal use thereof
|
|
AU2006202394A1
|
|
A process for inhibiting complement activation via the alternative pathway
|
|
AU2006202317A1
|
|
Discovery of therapeutic products
|
|
WO2006104978A2
|
|
Antibodies against the tenascin major antigens
|
|
AU2006200868A1
|
|
Human Antibodies Derived From Immunized Xenomice
|
|
AU2006200247A1
|
|
Methods and Compositions for Inhibiting Polypeptide Accumulation Associated with Neurological Disorders
|
|
WO2006081139A2
|
|
Antibodies against interleukin-1 beta
|
|
WO2006055704A2
|
|
Antibodies directed to ten-m proteins and uses thereof
|
|
WO2006001965A2
|
|
Reducing the risk of human anti-human antibodies through v gene manipulation
|
|
US2005100546A1
|
|
Human monoclonal antibodies to epidermal growth factor receptor
|
|
US2005287630A1
|
|
Human antibodies derived from immunized xenomice
|
|
US2005241006A1
|
|
Human antibodies derived from immunized xenomice
|
|
CN1930187A
|
|
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
|
AU2004224390A1
|
|
Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof
|
|
AU2004200848A1
|
|
Production of a multimeric protein by cell fusion method (D1)
|
|
WO2004055164A2
|
|
System and method for stabilizing antibodies with histidine
|
|
WO2004050683A2
|
|
Antibodies directed to tumor necrosis factor and uses thereof
|
|
AU2003299581A1
|
|
Antibodies against drugs of abuse
|
